About Transcription termination factor 2
Transcription termination factor 2 (TTF2) is a protein
from Homo sapiens identified by UniProt accession
Q9UNY4, 1162 residues long.
MolForge cross-references it against 0 known binders and
7 disease associations.
Target properties
| Protein name | Transcription termination factor 2 |
|---|
| UniProt accession | Q9UNY4 |
|---|
| Gene | TTF2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1162 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (7)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.50
- metabolite measurement · score 0.07
- large cell medulloblastoma · score 0.01
- vulvar intraepithelial neoplasia · score 0.00
- nasopharyngeal neoplasm · score 0.00
- breast cancer · score 0.00
- hepatocellular carcinoma · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9UNY4-F1 | alphafold | PREDICTED | 62.09 | — |
Amino-acid sequence (1162 residues)
MEEVRCPEHG TFCFLKTGVR DGPNKGKSFY VCRADTCSFV RATDIPVSHC LLHEDFVVEL QGLLLPQDKK EYRLFFRCIR SKAEGKRWCG SIPWQDPDSK EHSVSNKSQH ASETFHHSSN WLRNPFKVLD KNQEPALWKQ LIKGEGEEKK ADKKQREKGD QLFDQKKEQK PEMMEKDLSS GLVPKKKQSV VQEKKQEEGA EIQCEAETGG THKRDFSEIK SQQCQGNELT RPSASSQEKS SGKSQDVQRE SEPLREKVTQ LLPQNVHSHN SISKPQKGGP LNKEYTNWEA KETKAKDGPS IQATQKSLPQ GHFQERPETH SVPAPGGPAA QAAPAAPGLS LGEGREAATS SDDEEEDDVV FVSSKPGSPL LFDSTLDLET KENLQFPDRS VQRKVSPASG VSKKVEPSDP VARRVYLTTQ LKQKKSTLAS VNIQALPDKG QKLIKQIQEL EEVLSGLTLS PEQGTNEKSN SQVPQQSHFT KTTTGPPHLV PPQPLPRRGT QPVGSLELKS ACQVTAGGSS QCYRGHTNQD HVHAVWKITS EAIGQLHRSL ESCPGETVVA EDPAGLKVPL LLHQKQALAW LLWRESQKPQ GGILADDMGL GKTLTMIALI LTQKNQEKKE EKEKSTALTW LSKDDSCDFT SHGTLIICPA SLIHHWKNEV EKRVNSNKLR VYLYHGPNRD SRARVLSTYD IVITTYSLVA KEIPTNKQEA EIPGANLNVE GTSTPLLRIA WARIILDEAH NVKNPRVQTS IAVCKLQACA RWAVTGTPIQ NNLLDMYSLL KFLRCSPFDE FNLWRSQVDN GSKKGGERLS ILTKSLLLRR TKDQLDSTGR PLVILPQRKF QLHHLKLSED EETVYNVFFA RSRSALQSYL KRHESRGNQS GRSPNNPFSR VALEFGSEEP RHSEAADSPR SSTVHILSQL LRLRQCCCHL SLLKSALDPM ELKGEGLVLS LEEQLSALTL SELRDSEPSS TVSLNGTFFK MELFEGMRES TKISSLLAEL EAIQRNSASQ KSVIVSQWTN MLKVVALHLK KHGLTYATID GSVNPKQRMD LVEAFNHSRG PQVMLISLLA GGVGLNLTGG NHLFLLDMHW NPSLEDQACD RIYRVGQQKD VVIHRFVCEG TVEEKILQLQ EKKKDLAKQV LSGSGESVTK LTLADLRVLF GI
Explore Transcription termination factor 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets